Saptak Chem and Business Limited reported a narrowed standalone net loss of ₹4.85 lakh for the quarter ended June 30, 2026 (Q1FY26), compared to a loss of ₹12.49 lakh in the previous quarter (Q4FY26). The improvement was driven by a significant reduction in operating expenses, with total expenses falling to ₹4.85 lakh from ₹12.49 lakh in Q4FY26. The company, which operates in a single segment, recorded zero revenue from operations and other income during the period. This quarterly result marks a notable stabilization in cost management for the Ahmedabad-based firm.

The Board of Directors approved the unaudited financial results on August 01, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and independently reviewed by P.H. Shah & Co., Chartered Accountants, the company’s statutory auditors. The auditor’s review report confirmed that the financial statements comply with Ind AS 34 and contain no material misstatements. Management noted that due to the seasonality of its business, the Q1FY26 results are not indicative of full-year performance.

In other corporate developments, the Board appointed Ayush Tated as the Managing Director of Saptak Chem and Business Limited. The appointment includes defined terms, conditions, and remuneration, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the Director’s Report for the fiscal year ended March 31, 2026, and adopted the Secretarial Audit Report as required under Section 204(l) of the Companies Act, 2013.

The company has convened its 47th Annual General Meeting (AGM) for August 28, 2026, at 11:30 a.m. (IST), to be held via Video Conferencing. Shareholders will vote on the appointment of Ayush Tated as MD and other routine matters. Mrs. Rupal Patel, a Practicing Company Secretary, has been appointed as the Scrutinizer for remote e-voting and voting at the AGM. The Register of Members and Share Transfer Books will remain closed from August 22, 2026, to August 28, 2026, inclusive, to determine entitlements for the meeting.

Financial Performance Overview

Note: Figures are in ₹ Lakhs. Source: Saptak Chem and Business Limited.

What the Numbers Show

The primary driver of the improved bottom line in Q1FY26 was a sharp decline in "Other Expenses," which dropped to ₹4.05 lakh from ₹10.38 lakh in Q4FY26. This reduction more than offset a slight increase in employee benefits expense, which rose to ₹0.80 lakh from ₹0.45 lakh year-on-year. With revenue remaining at zero, the narrowing loss reflects strict cost containment rather than operational growth. The paid-up equity share capital stood at ₹307.32 lakh, up from ₹107.32 lakh in the previous quarter, indicating recent capital infusion or share issuance activity that diluted earnings per share impact despite the lower absolute loss.